Segall Bryant & Hamill LLC Grows Position in Pfizer Inc. (NYSE:PFE)

Segall Bryant & Hamill LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 4.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 76,539 shares of the biopharmaceutical company’s stock after acquiring an additional 3,177 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Pfizer were worth $2,031,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. United Bank increased its position in shares of Pfizer by 3.7% during the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after acquiring an additional 1,277 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Pfizer by 67.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,801 shares of the biopharmaceutical company’s stock valued at $428,000 after purchasing an additional 5,959 shares during the last quarter. Loomis Sayles & Co. L P boosted its holdings in shares of Pfizer by 7.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 8,450 shares of the biopharmaceutical company’s stock worth $245,000 after buying an additional 577 shares during the last quarter. FMR LLC grew its position in Pfizer by 3.1% during the third quarter. FMR LLC now owns 14,478,489 shares of the biopharmaceutical company’s stock valued at $419,007,000 after buying an additional 435,311 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in Pfizer during the third quarter worth about $1,685,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.8 %

Shares of PFE stock opened at $25.20 on Friday. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The business’s fifty day moving average is $26.06 and its 200 day moving average is $26.94. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $142.93 billion, a PE ratio of 17.87, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the firm posted $0.10 EPS. The company’s revenue was up 24.7% compared to the same quarter last year. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 0.06% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Bank of America reiterated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Citigroup dropped their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.